EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment

Surinder S Birring, Peter V Dicpinigaitis, Toby M Maher, Stuart B Mazzone, Clive P Page, Amale Hawi, Thomas Sciascia, Alyn H Morice

Lung · 2025

DOI: 10.1007/s00408-025-00812-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Lung, 2025. Verfasst von Surinder S Birring und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, King's College London, London, UK. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Cough, Receptors, Opioid, kappa, Antitussive Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic cough is a significant burden on patient quality of life and is associated with poor health outcomes. Chronic cough may be a result of neural hypersensitivity due to changes in both the peripheral and the central nervous systems, although the exact mechanisms underlying its pathogenesis are not completely understood. Opioid receptors, specifically kappa and mu, are potential therapeutic targets in the management of chronic cough because they play a pivotal role in both the peripheral and the central neural pathways implicated in the act of coughing. Morphine, a mu opioid receptor agonist, is an effective cough modulator; however, mu receptor agonists are part of a drug class that can induce respiratory depression and euphoria, with strong reinforcing properties that may lead to excessive use and abuse. Drugs with a dual-acting mechanism of kappa receptor agonism and mu receptor antagonism may be effective in the management of chronic cough without the potential for abuse. This review summarizes the current understanding of the mechanisms of cough hypersensitivity, the role of the kappa and mu receptors in the neurophysiology of cough, and the clinical potential of targeting these receptors as a novel way of managing chronic cough.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, muCoughReceptors, Opioid, kappaAntitussive AgentsHumansChronic DiseaseAnimalsAnalgesics, OpioidChronic Cough

Stichwörter der Autor:innen

Chronic coughHypersensitivityKappa agonismMu antagonismNalbuphineOpioid receptors

Substanzen

Receptors, Opioid, muReceptors, Opioid, kappaAntitussive AgentsAnalgesics, Opioid

Autor:innen und Institutionen

  • Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, King's College London, London, UK.
  • Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
  • University of Southern California, Los Angeles, CA, USA.
  • Fibrosis Research Group, National Heart and Lung Institute, Imperial College London, London, UK.
  • University of Melbourne, Melbourne, VIC, Australia.
  • Trevi Therapeutics, Inc, New Haven, CT, USA.

Zitieren

APA

Birring, S. S., Dicpinigaitis, P. V., Maher, T. M., Mazzone, S. B., Page, C. P., Hawi, A., Sciascia, T., & Morice, A. H. (2025). Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment. Lung. https://doi.org/10.1007/s00408-025-00812-8

Vancouver

Birring SS, Dicpinigaitis PV, Maher TM, Mazzone SB, Page CP, Hawi A, et al. Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment. Lung. 2025. doi:10.1007/s00408-025-00812-8

BibTeX
@article{Birring2025,
  author = {Birring, Surinder S and Dicpinigaitis, Peter V and Maher, Toby M and Mazzone, Stuart B and Page, Clive P and Hawi, Amale and Sciascia, Thomas and Morice, Alyn H},
  title = {Kappa and Mu Opioid Receptors in Chronic Cough: Current Evidence and Future Treatment},
  journal = {Lung},
  year = {2025},
  doi = {10.1007/s00408-025-00812-8}
}
Kostenlos starten →